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Abstract
Overexpression of p21-activated kinase 1 (PAK1) occurs during the progression of human breast cancer. We have
investigated the role of PAK1 in the premalignant progression of the MCF10 series of human breast epithelial
cell lines. Levels of PAK1 expression and activation increased with premalignant progression, and expression of
dominant-negative (DN) PAK1 reduced both cell proliferation and migration/invasion. In three-dimensional (3D)
overlay cultures in reconstituted basement membrane, the MCF10 series produced an in vitro model for pre-
malignant progression. MCF10AneoT cells formed a hyperplastic morphology in which some spheroids developed
abnormal lumens. The MCF10.AT1 line exhibited an atypical hyperplastic morphology of abnormal spheroid clus-
ters that did not form lumens. The MCF10.DCIS cells exhibited dysplastic growth. Expression of DN-PAK1 pro-
moted lumen formation in 3D-cultured MCF10A, NeoT, and AT1 structures, suggesting partial reversion of the
premalignant phenotype, but did not affect the atypical budding of AT1 structures or the dysplastic growth of duc-
tal carcinoma in situ structures. Aberrant proteolysis is another important characteristic of breast cancer progres-
sion and invasion. DN-PAK1 or knock-down of PAK1 reduced pericellular proteolysis of DQ-collagen IV in the 3D
cultures. Treatment of cells with an inhibitor of Rac1 also reduced pericellular proteolysis, and this reduction was
reversed by the expression of activated PAK1. Our conclusion is that overexpressed and activated PAK1 may be a
key coordinator of aberrant cell survival and proteolysis in breast cancer progression.
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Introduction
The malignant progression of breast cancers from normal mammary
epithelia requires multiple alterations at both genetic and epigenetic
levels [1]. Although deregulated expression or mutation of an onco-
gene or loss of function of a tumor suppressor gene may be the ini-
tiating event of cellular transformation, it is not normally sufficient
[2] and so requires successive or concurrent alterations in the expres-
sion of a panel of other important genes to produce or maintain a
premalignant/malignant phenotype [3–5]. p21-Activated kinase 1
(PAK1) [6] is a candidate to be one of these factors, because it is
required for oncogenic Ras-induced transformation of Rat-1 fibro-
blasts [7], for Rac3-controlled proliferation of breast cancer cells
[8], and for Vav3-induced transformation, motility, and morphologic
changes of NIH3T3 cells [9]. PAK1 is an immediate downstream
effector of Rac/Cdc42 small GTPases, active lipids, GRB2a, PIX/
Cool, and NCK adaptor proteins that receive extensive upstream cell
signals from receptor kinases, G-proteins, and Ras small G proteins
[10–13]. Activated PAK1 regulates many essential cell signal pathways
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involving the cell cycle, cytoskeleton reorganization and motility, gene
expression, and survival and proliferation [14]. PAK1 expression is
significantly increased in colorectal and ovarian cancers [15,16] and
in primary breast cancers [17]. Amplification of the PAK1 gene occurs
in bladder, ovarian, and breast cancers [16,18,19]. In breast cancer,
PAK1 amplification predicts tumor recurrence and resistance to tamox-
ifen therapy [20], whereas transgenic overexpression of PAK1 alone is
sufficient to induce breast tumorigenesis in animal models [21]. These
findings could indicate that PAK1 may be a therapeutic target candidate
for treatment of cancers. For example, direct inhibition of PAK1 ac-
tivity by expressing a dominant-negative mutant, PAK1.K299R (DN-
PAK1), suppresses cellular motility and invasiveness in MDA-MB-435
and MCF-7 breast cancer cells [22–24], and increases chemotherapeutic-
induced cell killing of renal carcinoma cell lines [25]. Conversely, the
expression of a constitutively activated PAK1.T423E (CA-PAK1)
increases cell motility, mitosis, anchorage-independent growth, and
invasiveness in MCF-7 breast cancer cells [24]. Overall, there is ex-
tensive evidence for the involvement of PAK1 in metastatic human
breast cancer [18].
PAK1 overexpression in human breast cancer may occur in the
early stages, with marked increase during the conversion of normal
epithelium to ductal carcinoma in situ (DCIS) [26]. Thus, it is impor-
tant to consider whether PAK1 may contribute to the premalignant
progression of the disease. In immortalized but untransformed cells,
DN-PAK1 induces resistance to Ras transformation in Rat-1 fibroblasts
[7] and promotes detachment-induced cell death (also termed anoikis)
in MCF10A breast epithelial cells [27]. CA-PAK1 rescues MCF10A
cells from undergoing anoikis [27]. A Rac/PAK pathway that is acti-
vated by the extracellular matrix through integrin α6β4 supports cell
survival signaling in breast epithelial cells through NF-κB [28].
In normal breast tissues, the epithelial cells are organized both struc-
turally and functionally in a specialized glandular architecture with
polarized cell–cell and cell–basement membrane contacts [29]. Pre-
invasive and invasive epithelial tumors are notable for progressive dis-
ruptions of this normal morphology [30]. Human mammary tumor
cell lines are useful tools for understanding breast carcinogenesis; how-
ever, it may be difficult to correlate results from studies of biologic
pathways in two-dimensional (2D) cell culture to clinical aspects of
breast tumors. For example, traditional cell culture techniques have
limited relevance to the pathophysiological context of breast tissue
[29]. In contrast, three-dimensional (3D) culture using reconstituted
basement membrane (rBM) better recapitulates both structural and
functional cues of breast tissue [30]. Mammary epithelial cells grown
in 3D rBM overlay cultures form spheroids with lumens (commonly
called acini), and thus resemble secretory alveoli in the normal breast
tissue [30,31].
Long-established breast cancer cell lines isolated from clinical speci-
mens (e.g., MCF-7, BT20, MDA-MB-231, etc.) have been routinely
used as cell models in experimental cancer biology. A problem with
using these cell lines for studies of breast cancer progression is that
they were derived from tumor metastases, such as pleural effusions,
far from the primary tumors [32]. Progression series cell models de-
rived from nontumorigenic breast epithelial cells may provide clearer
clues to the genetic and epigenetic changes that underlie tumor pro-
gression. For example, HMT-3522 human mammary epithelial cells
and their tumor progression series derived by continuous cell passag-
ing in defined medium are well-established and are used for molecular
and cellular studies of cancer [33]. Another model is derived from
MCF10A cells, which are a spontaneously immortalized human
breast epithelial cell line that was developed from a patient who un-
derwent a reduction mammoplasty [34]. MCF10A cells are pseudo-
diploid and form typical cobblestone epithelial sheets in monolayer
culture and do not survive as xenografts in immunodeficient mice
[34]. Stable transfection of MCF10A cells with the T24 Ha-Ras on-
cogene produced the MCF10AneoT (NeoT) line [35]. NeoT cells
exhibit some aspects of the malignant phenotype in that they can form
xenograft lesions, with characteristics of mild to moderate [grades 1
and 2] hyperplasia [36]. The validity of this model is based on the
functional activation of Ras in human breast cancers due to over-
expressed growth factors and their receptors [37], and the evidence
that Ras-directed therapeutics may be useful in breast cancer treat-
ment [38], although Ras mutations per se are not common. Further
confirmation comes from the use of gene expression signatures to de-
fine Ras pathway activation; these studies found that Ras activation is
prevalent in breast cancer and that this signature is predictive of sen-
sitivity to Ras-directed therapeutics [39]. By serial passaging of NeoT
xenograft lesions in vivo, a more advanced cell line was isolated and
named MCF10.AT1 (AT1). AT1 cells produce xenograft lesions with
characteristics of atypical [grade 3] hyperplasia [36]. After further se-
rial passages in vivo, MCF10.DCIS.com (DCIS) cells were isolated.
As xenografts, DCIS cells initially form lesions with the characteristics
of comedo ductal carcinoma in situ, which may progress to invasive
carcinoma over time [3]. Thus, the MCF10A variants that grow as
orthotopic xenografts constitute an in vivo model for the analysis of
progression of premalignant breast disease.
Materials and Methods
Reagents
Dulbecco’s modified Eagle’s medium (DMEM)/F12, sodium pyru-
vate solution, l-glutamine solution, horse serum, PBS, human epider-
mal growth factor (EGF), gelatin, Lipofectamine 2000, and DNA
oligonucleotides were purchased from Invitrogen (Carlsbad, CA).
DMEM, trypsin/EDTA solution, and penicillin–streptomycin were
obtained from Cellgro (Herndon, VA). Fetal bovine serum (FBS)
was from HyClone (Logan, UT). Protease-inhibitor cocktail tablets
were obtained from Roche (Indianapolis, IN). Basement membrane
matrix (Matrigel) was obtained from BD Biosciences (Bedford, MA).
Quenched fluorescein-conjugated collagen type IV (DQ-collagen IV)
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) were obtained from Molecular Probes (Eugene, OR). Rac1 in-
hibitor (NSC23766) was obtained from Calbiochem (La Jolla, CA).
Enhanced chemiluminescence Western blot analysis detection reagents
were purchased from Amersham Biosciences (Piscataway, NJ). DRAQ5
vital DNA stain was purchased from Biostatus (Shepshed, UK). Bovine
serum albumin (BSA), fibronectin (from human plasma), chicken oval-
bumin, hexadimethrine bromide (polybrene), hydrocortisone, and
other chemicals not otherwise listed were obtained from Sigma (St.
Louis, MO). Rabbit anti-PAK1, rabbit anti-PAK2, rabbit anti-PAK3,
rabbit anti–phospho-PAK1 (Thr423)/PAK2 (Thr402), mouse anti–
myc-tag (9B11), rabbit anti–phospho-LIM kinase 1 (Thr508)/LIM ki-
nase 2 (Thr505), and rabbit anti–cleaved caspase 3 (Asp175) antibodies
were purchased from Cell Signaling Technology (Beverly, MA). Rabbit
anti–phospho-cofilin (Ser3) and horseradish peroxidase–conjugated
goat anti–rabbit IgG and horseradish peroxidase–conjugated goat
anti–mouse IgG antibodies were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Mouse anti–tubulin antibody was obtained
fromDevelopmental Studies Hybridoma Bank (Iowa City, IA). Oregon
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green-488–conjugated goat anti–rabbit IgG, Alexa Fluor-568 conju-
gated phalloidin, and 4′,6-diamidino-2-phenylindole (DAPI) were pur-
chased from Molecular Probes.
The retrovirus expression vector pLNCX2, the enhanced green fluo-
rescent protein (EGFP) coexpressing vector pIRES2-EGFP, and the
Discosoma red fluorescent protein (RFP) coexpressing vector pIRES2-
DsRed-Express were purchased from BD Clontech Laboratories
(Mountain View, CA). PfuUltra high-fidelity DNA polymerase,
XL10-Gold Ultracompetent E. coli, and retrovirus packaging vectors
pVPack-GP and pVPack-VSV-G were purchased from Stratagene (La
Jolla, CA).
Cell Lines and Culture
MCF10A, NeoT, AT1, and DCIS cell lines were obtained from
the Cell Lines Resource (Karmanos Cancer Institute, Detroit, MI).
Cells were maintained as monolayers in DMEM/F12 containing 5%
horse serum, 20 ng/ml EGF, 0.5 μg/ml hydrocortisone, 10 μg/ml
insulin, 50 U/ml penicillin, and 50 μg/ml streptomycin at 37°C
and 5% CO2. For 3D culture, each 12-mm round coverslip was
coated with 40 μl of ice-cold rBM (Matrigel) and incubated at
37°C for 20 minutes to allow the rBM to solidify. The coated cover-
slips were placed in a 24-well plate with the rBM facing up. A tryp-
sinized single cell suspension containing 5000 cells in a 40-μl volume
of the assay medium [DMEM/F12 containing 2% horse serum,
5 ng/ml EGF, 0.5 μg/ml hydrocortisone, 10 μg/ml insulin, 50 U/ml
penicillin, 50 μg/ml streptomycin, and supplemented with 2% (v/v) of
Matrigel] was carefully loaded on top of the rBM, and the plate was
incubated at 37°C for 30 minutes to let the cells attach to the rBM.
Then, 500 μl of the assay medium was added per well, and the cells
were cultured at 37°Ca and 5% CO2, with the medium being changed
every 4 days.
Plasmid Construction
Gene inserts of wild-type PAK1 (wt-PAK1) and three mutant forms,
namely, a constitutively activated mutant PAK1.T423E (CA-PAK1)
and two dominant-negative mutants of PAK1 (DN-PAK1), PAK1.
K299R and PAK1.H83,86L,K299R, all with myc epitope tags at the
N-terminus, were prepared using polymerase chain reaction from their
parental plasmids. The primers were designed to introduce two new
restriction enzyme digestion sites: a 5′ Hind III site and a 3′ NotI site.
PfuUltra high-fidelity DNA polymerase was used to facilitate correct
amplification of the 1.6-kb-long sequences. After double-enzyme diges-
tion with Hind III and NotI, the PAK1 inserts were ligated into the
pLNCX2 retroviral vector, and then their sequences were confirmed.
Internal ribosomal entry site (IRES) 2–EGFP or IRES2-RFP elements
were polymerase chain reaction–prepared using a pair of primers intro-
ducing a 5′ NotI site and a 3′ ClaI site. After double-enzyme digestion
with NotI and ClaI, the IRES2-EGFP or IRES2-RFP elements were
ligated into the pLNCX2-PAK1 plasmids to form the pLNCX2-
PAK1-IRES2-EGFP and pLNCX2-PAK1-IRES2-RFP series of retro-
virus constructs. The IRES2-EGFP or IRES2-RFP element was also
ligated into the pLNCX2 to form control constructs.
To knock-down PAK1 expression, PAK1 siRNA hairpin oligo-
nucleotide sequences and a nonspecific shRNA control sequence
(BD Clontech) were separately cloned into RNAi-Ready pSIREN-
RetroQ-DsRed-Express retrovirus vector (BD Clontech) according
to the manufacturer’s instructions. The first siRNA sequence, CAU-
CAAAUAUCACUAAGUC, which targets PAK1 326 to 344, was de-
rived from a previous publication [40]. The second siRNA sequence
CUCGAAGAAGACAUCCAAC, which targets PAK1 396 and 414,
was designed using an online siRNA designer tool (http://bioinfo.
clontech.com/rnaidesigner/frontpage.jsp).
Retrovirus Production and Infection of MCF10A
Progression Series
HEK293T cells were maintained at 37°C in DMEM containing
10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin and supple-
mented with 4 mM l-glutamine, and 1 mM sodium pyruvate until
90% confluent. For transfection, the medium was changed to omit
the antibiotics. Then, the cells were triply transfected with equal
amounts of the retrovirus construct, pVPack-GP plasmid, and pVPack-
VSV-G plasmid using Lipofectamine 2000 reagent according to the
manufacturer’s instructions. The medium was changed 6 hours after
transfection, and the cells were cultured at 37°C for 16 hours when
extensive expression of the reporter EGFP or RFP proteins could be
monitored by fluorescent microscopy. The transfection efficiency was
∼100% based on fluorescence. The medium was changed and the cells
were cultured at 30°C for 24 hours for the production of retroviruses.
The virus broth was collected and centrifuged for 5 minutes at 200g to
remove cell debris. Fresh medium was added and the HEK293 cells
were continued to culture for 24 hours at 30°C to harvest a second
batch of virus broth. Typically, for a 35-mm dish, 1 ml of virus broth
was harvested in each batch.
The supernatant broth containing viruses was supplemented with
polybrene at a final concentration of 12 μg/ml by the addition of a
4-mg/ml polybrene stock solution. Cells of the MCF10A progres-
sion series were trypsinized, centrifuged, and resuspended in growth
medium to form single cell suspensions at a concentration of 2 ×
106 cells/ml. The cell suspensions were mixed (3:1 v/v ratio) with
virus mixture, plated onto tissue culture dishes at low starting con-
fluence (typically ∼5%), and cultured at 37°C. The next day, the me-
dium was changed, and the cells were subjected to a second round
of infection using the second batch of viruses as described above. On
the third day, the medium was changed again, and the culture con-
tinued. Virus transduction efficiency was checked using fluorescent
microscopy, and the cells were used for experiments. Optimization of
virus production and infection conditions/parameters in this way pro-
duced ∼95% infection efficiency.
Western Blot Assays
Cell lysates were made in a lysis buffer, composed of 50 mM Tris–
HCl, pH 7.4, 100 mM NaCl, 10 mM sodium pyrophosphate,
2 mM EDTA, 1% Nonidet P-40, 1% sodium deoxycholate, 2% so-
dium dodecyl sulfate, 0.1% 2-mercaptoethanol, 10% glycerol, and
0.005% bromophenol blue, and supplemented with protease in-
hibitors (Roche) according to the manufacturer’s instructions. For
detecting phosphorylated proteins, this lysis buffer was further sup-
plemented with 50 mM sodium fluoride, 0.2 mM sodium ortho-
vanadate, and 1 μM okadaic acid. The cell lysates were subjected
to brief sonication on ice, heated at 100°C for 5 minutes, and loaded
onto SDS-PAGE gels for electrophoresis. The proteins were then
transferred onto nitrocellulose membrane and were incubated in
blocking buffer: 2% BSA, 0.5% chicken ovalbumin, 25 mM Tris–
HCl, pH 7.4, 135 mM NaCl, 3 mM KCl, 50 mM sodium fluoride,
0.2 mM sodium orthovanadate, and 0.3% Tween-20. This blocking
buffer was also used for the dilution of antibodies. Membranes were
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stripped for subsequent probing with additional antibodies as de-
scribed [41].
Cell Proliferation Assay
This assay is based on the ability of living cells to convert MTT into
insoluble formazan precipitate that can be dissolved in DMSO and be
quantified using a spectrometer. The absorbance values are pro-
portional to the live cell number [42]. Cells were infected with viruses,
trypsinized into single cell suspensions, and inoculated into 96-well
plates with 103 cells/well in 200 μl of growth medium. The plates
were cultured at 37°C and 5% CO2 for the times shown. On the
day of the assay, 20 μl of MTT (5 mg/ml) stock solution was added
into each well, and the plate was incubated at 37°C and 5% CO2 for
4 hours for the formation of formazan. The medium was removed,
and 150 μl of DMSO was added into each well to dissolve the forma-
zan precipitate. The absorbance values at 485 nm were determined
using a plate reader (SpectraFluor Plus; Tecan, Salzburg, Austria).
Cell Migration/Invasion Assay
Cell migration/invasion assays through a minimal barrier were per-
formed using blind well chambers and polycarbonate membranes
(NeuroProbe, Gaithersburg, MD). The procedure was based on the
manufacturer’s instructions with the modifications we previously de-
scribed [43]. Briefly, polycarbonate membranes (12-μm pore, 13-mm-
diameter, polyvinyl pyrrolidone–free) were soaked (both sides) in
1% gelatin solution and were air-dried to block the pores. Then, the
upper side of the membrane was coated with 30 μl of 0.4 mg/ml
Matrigel diluted in distilled water and then air-dried. The lower side
of the membrane was further coated with fibronectin by wetting with
10 μg/ml fibronectin solution and was air-dried. The lower chamber
of the blind well chamber set was filled with 214 μl of DMEM/F12
containing 10% FBS as chemoattractant, and the coated membrane
was gently placed on top of the lower chamber without making air
bubbles. The upper chamber was filled with 200 μl of DMEM/F12
containing 0.1% BSA. Cells were trypsinized into single cell suspen-
sions and washed twice with DMEM/F12; 50,000 cells were loaded
into the upper chamber and the cells were incubated at 37°C and
5% CO2 for 24 hours. The membrane was removed, washed briefly
with PBS, and fixed with 4% paraformaldehyde for 20minutes at room
temperature. The cells were then permeabilized with 0.5% Triton X-
100 in PBS for 10 minutes, quenched with 0.75% glycine in PBS, and
stained with DAPI for nuclei. Finally, the membrane was mounted on a
slide and sealed with a coverslip. Confocal fluorescent images of the
DAPI-stained nuclei of both the cells on the upper side of the mem-
brane (which had not migrated) and the cells on the lower side of the
membrane (which had migrated) were taken in separate confocal sec-
tions at the appropriate z-axis. Cell numbers were counted based on the
number of the nuclei. Migration/invasion activity was expressed as the
percentage of cells that had migrated.
Immunofluorescence and Confocal Microscopy
MCF10A series cells growing on Matrigel-coated coverslips were cul-
tured in 24-well plates. To fix structures, the coverslips were briefly
washed with PBS at 37°C and incubated in 4% paraformaldehyde,
pH 7.5 in PBS for 20 minutes at room temperature. The fixation was
quenched by three washes with 0.75% glycine in PBS. Then, the cellu-
lar structures were permeabilized with 0.5% Triton X-100 in PBS for
10 minutes at 4°C and blocked with a 1-hour incubation in immuno-
fluorescence (IF) buffer: 130 mM NaCl, 7 mM Na2HPO4, 3.5 mM
NaH2PO4, 0.1% BSA, 0.2% Triton X-100, and 0.05% Tween-20,
pH 7.5. Structures were incubated at 4°C with primary antibody in
IF buffer overnight in a humidified chamber. After washing three times
with IF buffer, the coverslips were further incubated with the fluorescent-
conjugated secondary antibodies together with other fluorescent cellular
staining reagents (e.g., DAPI, Alexa Fluor-568 phalloidin) at room tem-
perature for 2 hours. After three washes with IF buffer, the coverslips
were either mounted onto slides or placed in a 35-mm dish with PBS
and imaged with a confocal microscope (LSM 510; Zeiss, Göttingen,
Germany) as described previously [44].
Figure 1. Increase in PAK1 expression and activation in the MCF10
progression series grown in vitro. (A) Lysates of MCF10A, NeoT,
AT1, and DCIS cells were subjected to immunoblot analysis for ex-
pression of group 1 PAKs [PAK1, PAK2, and PAK3]. The membranes
were stripped and reprobed for tubulin to verify equal loading. (B)
Densitometric analyses of PAK1 levels from four independent ex-
periments were normalized to the level in MCF10A cells in each ex-
periment. Data are mean ± SEM. One-way ANOVA shows that
there is a significant increase in PAK1 level (P < .05) at each pro-
gression step. (C) MCF10 series cells were cultured in the presence
of 75 μM NSC23766 (Rac inhibitor) or vehicle for 8 hours, followed
by a further 2 hours in serum-free medium with 1 μM okadaic acid
(phosphatase inhibitor) and ± NSC23766. Lysates were Western
blotted first for phosphorylated PAK1 and then the membranes
were stripped and reprobed for tubulin.
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Assay of Proteolysis By Live Cells
Fluorescence-quenched DQ-collagen IV was added into the
Matrigel at a concentration of 25 μg/ml. Coverslips coated with
40 μl of the supplemented Matrigel were loaded with 5000 single
cells suspended in 50 μl of the assay medium. The cells were then
subjected to 3D culture in 24-well plates for 2 days in 500 μl of the
assay medium, in the presence or absence of treatments as indicated.
Small spheroidal structures developed from single cells, and they were
then stained for nuclei with DRAQ5 diluted in DMEM/F12 at
1:3000 for 30 minutes. Confocal microscopic images were taken
using dipping objective lenses. Quantification of pericellular pro-
teolysis at equatorial cross-sections of spheroids was performed using
a software (MetaMorph Premiere version 7.0; Molecular Devices,
Sunnyvale, CA). Red fluorescent protein expression (red channel)
and DRAQ5-stained nuclei (blue channel) were used to demarcate
cellular boundaries to exclude any signal from intracellular activity.
For 3D reconstruction, z-axis image stacks were acquired through
the spheroids at a slice thickness of 1 μm.
Statistical Analysis
For quantitative data analysis, the results were plotted as the
mean ± SEM. Statistical analysis was performed using GraphPad Prism
version 3.0a (GraphPad Software Inc., San Diego, CA). Statistical sig-
nificance was determined using Student’s t tests, or for multiple com-
parisons using one-way analysis of variance (ANOVA). For enumeration
data analysis, the results were plotted as the frequencies. Statistical sig-
nificance between groups was determined using chi-square analysis.
Results
PAK1 Expression Level Increases in Correlation with
Premalignant Progression of the MCF10A Series
Endogenous PAKs have been reported to be elevated at both the ex-
pression level [17,45] and the activation level [46] in breast cancer cells,
with evidence that PAK1 overexpression occurs during the conversion of
normal epithelium to ductal carcinoma in situ [26]. We therefore tested
whether there was a change in the expression levels of group I PAKs
in the MCF10A breast cancer progression series. Specific PAK1,
PAK2, and PAK3 antibodies were used, and the target bands were
detected separately by Western blot analysis (Figure 1A). PAK1 ex-
pression levels were found to increase through the progression series
of MCF10A, NeoT, AT1, and DCIS, with an approximately twofold
increase at each progression step (Figure 1B). In contrast, the levels of
PAK2 and PAK3 appeared constant throughout the progression series.
Although overexpression of PAK1 is likely to be significant, the ac-
tivity level of PAK1 may be a more direct indicator of its function.
PAK1 activation involves autophosphorylation at T423, generating
an epitope that has been used to raise antibodies for detecting PAK1
activation. MCF10A cells require growth factors and hormones for cell
proliferation and survival [34], and growth factors such as EGF and
insulin in the growth medium can stimulate many signaling cascades
that lead to the activation of PAK1 [12]. Indeed, in the regular growth
culture medium for the MCF10 cell series, there is a constitutive phos-
phorylation of PAK1 (data not shown). To determine whether PAK1
phosphorylation results from intrinsic molecular and cellular alterations
associated with progression, and not from the culture medium, we sub-
jected the cells to serum- and hormone-starvation for 2 hours before the
assay. The results showed that PAK1 phosphorylation levels increased
Figure 2. Expression of exogenous PAK1 constructs in MCF10
mammary epithelial progression series. (A) Cells were infected with
viruses expressing exogenous myc-tagged PAK1 constructs plus
EGFP, or EGFP only as the control. Cell lysates were subjected to
separate Western blot assays for the myc-tag and PAK1. Overex-
pression of the PAK1 constructs is apparent from comparison to
the signals for endogenous PAK1 in control cells exogenously ex-
pressing only EGFP. Equal loading per lane was shown by stripping
and reprobing for tubulin. (B) Typical confocal fluorescent images
showing equatorial slices through spheroids developed from single
virus–infected cells expressing myc-tagged PAK1 constructs and
coexpressing either RFP (red) or EGFP (green). Upper row: fluores-
cent confocal images of a spheroid cultured for 2 days; scale bar,
10 μm. Lower row: spheroid cultured for 7 days; scale bar, 50 μm.
Cell nuclei were stained with DAPI (blue).
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dramatically through the series of MCF10A, NeoT, AT1, and DCIS
(Figure 1C ). Among the known upstream regulators, Rac1 has been
delineated as a principal activator of PAK1 [6]. NSC23766, which is
a commercially available, small-molecule inhibitor of the activation of
Rac1 [47], significantly reduces the PAK1 phosphorylation level in
bone marrow cells [48]. Addition of NSC23766 to the MCF10A series
cells greatly reduced the level of PAK1 phosphorylated at T423 com-
pared with that in vehicle-treated cells (Figure 1C ).
Manipulation of PAK1 Activity By Retroviral Transduction
of the MCF10A Progression Series
To determine the functional significance of PAK1 overexpression
and activation during the progression of MCF10A cells, we devel-
oped retroviral vectors to manipulate PAK1 expression and activity.
Retroviral vectors have previously been used for the stable expression
of genes in MCF10A cells [29]. PAK1, CA-PAK1, and DN-PAK1
with N-terminal myc-tags were expressed from retroviral constructs
that include IRES elements that allow the transcription of a single
bicistronic mRNA of myc-PAK1-IRES2-FP, and so produce myc-
PAK1 together with EGFP or RFP as a reporter for expression of
PAK1. By optimizing infection conditions, approximately 95% in-
fection efficiency was acquired based on fluorescent microscopic
observation of the percentage of green or red fluorescent cells. By
Western blot analysis, the exogenous PAK1 in the lysates of all
the four cell lines was detected using the myc-tag antibody. Overex-
pression of PAK1 was observed by comparing to the control virus–
Figure 3. Inhibition of the proliferation of MCF10 progression series cells by DN-PAK1. Cells were passaged onto six-well plates (0.1 ×
106 cells/well) and infected with viruses expressing EGFP only (○) or EGFP plus wt-PAK1 (□), CA-PAK1 (Δ) or DN-PAK1 [PAK1.H83,86L,
K299R (•) and PAK1.K299R (▪)]. The infected cells were then passaged onto 96-well plates (1 × 103 cells/well) and cultured as shown
for assay of proliferation. Data are mean ± SEM from four independent experiments.
Figure 4. Inhibition of migration/invasion of MCF10 progression se-
ries cells by DN-PAK1. Cellular migration/invasion was assayed over a
24-hour period through a gelatin/Matrigel barrier in response to 10%
FBS as a chemoattractant in the lower chamber. Data are mean ±
SEM from three independent experiments. One-way ANOVA shows
that there is a significant (P< .05) inhibition of cell migration/invasion
by DN-PAK1 in all the cell lines.
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infected cells using the PAK1 antibody. All PAK1 constructs were
overexpressed to similar levels and to a relatively modest extent over
that of the endogenous protein (Figure 2A). Three-dimensional rBM
overlay culture of infected single cells reveals that they maintain ex-
pression of the fluorescent reporter proteins during subsequent pro-
liferation and development of structures (Figure 2B).
Expression of DN-PAK1 Inhibits Cell Proliferation
PAK1 activation has been shown to promote cell proliferation by
stimulating the cell cycle [49] and inhibiting apoptosis [27]. Repres-
sion of PAK1 kinase activity correlates with cellular senescence, an
irreversible cell cycle exit [50]. PAK1 activity is associated with pro-
liferation in MCF-7 breast cancer cells [51]. To determine whether
the enhanced PAK1 expression and activation that occurs in the
MCF10A progression series may play a role in cell proliferation,
we infected the four cell lines with the different PAK1-expressing
retroviruses. An MTT assay was used to monitor cell proliferation
over time. As shown in Figure 3, overexpression of wt-PAK1 or
CA-PAK1 had little effect on cell proliferation, whereas expression
of the two dominant-negative PAK1 mutants significantly inhibited
cell proliferation, monitored at day 6, compared with EGFP controls
for all four cell lines. In agreement with this result, we found that
DN-PAK1 tends to increase G1 and decrease S phase populations of
the cells (data not shown). By day 10, all the cultures of MCF10A and
NeoT cells reached similar ∼100% confluence, as monitored by micros-
copy and MTT assay values. In contrast, DN-PAK1–transduced AT1
and DCIS cells remained growth-inhibited compared with EGFP-, wt-
PAK1–, and CA-PAK1–transduced cells through day 10. Interestingly,
the kinase-dead only mutant (PAK1.K299R) exhibited a greater growth
inhibition at both days 6 and 10 than did the mutant that was both
kinase-dead and disrupted for p21-binding (PAK1.H83,86L,K299R),
in AT1 and DCIS cells. These findings suggest that downregulation
of PAK1 activity by expression of DN-PAK1 can efficiently inhibit cell
proliferation, with a much greater effect on the premalignant AT1 and
DCIS cells that exhibit greater endogenous expression and activation of
PAK1 (Figure 1), than on the more normal MCF10A cells.
Expression of DN-PAK1 Inhibits Cell Migration/Invasion
PAK1 regulates cytoskeleton reorganization and is thus likely to
control cell migration and invasion [52]. We therefore tested whether
alteration of PAK1 activity may affect cell migration/invasion in the
MCF10 progression series. In initial experiments, we found that the
invasive ability of all four cell lines was too weak to be measured
using protocols that have previously been reported for the assay of
Figure 5. Three-dimensional rBM overlay culture of the MCF10 progression series models hyperplastic, atypical hyperplastic, and dysplastic
stages. At the times shown, the structures were fixed and processed. Top row: Differential interference contrast (DIC) images of structures
with staining for: actin with phalloidin conjugated to Alexa Fluor-568 (red); DAPI as a marker of nuclei (blue); and cleaved caspase 3 as a marker
of apoptosis (green); scale bar, 20 μm. The fluorescent images were captured at the equatorial plane of the structures and overlaid on a DIC
image of the structure. Middle two rows: Alexa Fluor-568 phalloidin images of the actin cytoskeleton at a plane approximating the equatorial
section of themajority of the structures in the field; scale bar, 100 μm. Bottom row: DAPI-stained nuclei at a plane approximating the equatorial
section of the majority of the structures in the field; scale bar, 50 μm. Data are representative of results from three independent experiments.
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Figure 6. DN-PAK1 promotes luminal clearing in spheroids formed from cells of the MCF10 progression series in 3D rBM overlay cul-
ture. MCF10 series cells were cultured and transduced as indicated, with control retroviruses that only expressed EGFP, or bicistronic
constructs expressing EGFP plus wild-type PAK1 (wt), CA-PAK1 (423E), or two forms of DN-PAK1 (83,86L,299R or 299R). The structures
were fixed at the time shown, and the nuclei were stained with DAPI or DRAQ5. (A) Confocal sections at an equatorial plane through the
structures are shown. Images at day 10 for MCF10A and day 15 for the other cell lines are illustrated because these were the most
sensitive time points for observing the effects of PAK1 manipulation on hollow lumen formation. Data are representative of results from
four independent experiments. Scale bar, 50 μm. (B) Frequencies of occurrence of hollow lumen formation (% of total structures im-
aged). Images of at least 50 fields were collected for each condition and analyzed for formation of hollow structures, which were defined
by the absence of nuclear staining at the center of the structure. The total numbers of structures counted are listed in parentheses. To
determine whether there was a significant effect of each PAK construct on the formation of hollow structures, each condition was
compared to the EGFP control transduction in the same cell line by chi-square analysis (*P < .05, **P < .01).
Neoplasia Vol. 10, No. 4, 2008 PAK1 in 3D Model of Pre-Malignant Breast Cancer Li et al. 321
Figure 7. PAK1 regulates pericellular proteolysis in the MCF10 progression series grown in 3D rBM overlay cultures. (A and B) MCF10
series cells were infected with control retroviruses that only expressed RFP, or bicistronic constructs expressing RFP plus wild-type
PAK1 (wt), CA-PAK1 (423E), or two forms of DN-PAK1 (83,86L,299R or 299R) and cultured for 2 days in Matrigel plus DQ-collagen IV.
The nuclei of live cells were stained with DRAQ5 for 30 minutes, and then confocal immunofluorescent images were taken. (A) Expres-
sions of retroviral constructs (red) and nuclei (blue) are shown in equatorial sections of the cells along with the associated cleavage of
DQ-collagen IV (green). Scale bar, 10 μm. (B) Quantification of the green signals from the equatorial cross-sections of three to eight
structures for each condition. The data are presented as average pixel intensity per cell, with cell number determined by counting of
DRAQ5-labeled nuclei. CA-PAK1 significantly increased pericellular proteolysis, and both DN-PAK1 constructs significantly inhibited peri-
cellular proteolysis, compared to RFP control structures, in all cell lines (P < .05). (C) Representative quantification of the green signal
from 3D reconstructions of the MCF10A experiments shown in (A). The data are presented as average voxel intensity per cell from the
entire structure. Cell number was determined by counting the DRAQ5-labeled nuclei in z-stacks through the structures. (D and E) DCIS
cells were infected with dual sequence retroviruses that expressed RFP plus a control shRNA sequence (Ctl), or plus two forms of
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the invasive phenotype of MCF10A cells that have been transformed
with H-Ras.D12 [53]. Thus, we modified the method to include
coating of the polycarbonate membrane and alteration of the medium
compositions in the upper and lower chambers to provide a sub-
stantial and detectable control migration value for all of the cell lines.
Under our modified migration/invasion assay conditions, all cell lines
showed 10% to 15% cell migration. Overexpression of either wild-
type or CA-PAK1 in MCF10 series cells had no significant effect on
cell migration/invasion compared to the EGFP-only–infected control
cells (Figure 4). The two DN-PAK1 mutants dramatically decreased
the migration/invasion phenotype in all the four cell lines.
One defined pathway through which PAK can regulate cell motil-
ity is through phosphorylation of the LIM kinase, leading to the
phosphorylation of cofilin and inhibition of its actin-severing activity
[54]. In prostate carcinoma cells, for example, activation of PAK2
leading to the regulation of the LIM kinase/cofilin pathway has been
proposed to increase motility in response to α2-macroglobulin, a pro-
tease inhibitor [55]. We therefore tested whether the LIM kinase/
cofilin pathway was active in the MCF10 progression series and whether
it was regulated by PAK. Phospho–LIM kinase levels were relatively
constant through the MCF10 progression series and not affected by the
overexpression of wild-type, CA-, or DN-PAK1 (Figure W1). Phospho-
cofilin levels, however, were virtually undetectable in the normal
MCF10A cells and markedly increased through the progression series
to DCIS. Again, however, overexpression of wild-type, CA-, or DN-
PAK1 had no significant effect on phospho-cofilin levels (Figure W1).
Overall, the effect of DN-PAK1 to block migration/invasion does not
correlate with the regulation of the LIM kinase/cofilin pathway.
Three-Dimensional rBM Overlay Culture of the MCF10A
Progression Series Provides A Model of Hyperplasia, Atypia,
and Dysplasia
To develop a tractable in vitro model in which to study the role
of PAK1 expression and activation as a function of breast cancer
progression, we have extended an established model for analyzing
morphogenesis and oncogenic transformation of MCF10A cells in
a 3D laminin-rich rBM overlay culture system [29] to include the
MCF10A progression series. MCF10A cells have previously been
characterized in 3D rBM overlay culture as a model for normal mam-
mary epithelia that exhibits apicobasal polarity, cell–cell junctions,
strict control of cell proliferation, and apoptosis and in the formation
of functional glandular structures [30,56]. Single MCF10A cells in
rBM undergoes proliferation to form spheroids that develop into polar-
ized acini (Figure 5). Hollow lumen formation in the acinar structures
is because of growth arrest and detachment-induced apoptosis, also
termed anoikis [57], and autophagy [56]. Strong staining for cleaved
caspase 3 in the center of the MCF10A structures before the formation
of the lumen supports a predominant role for apoptosis in this process
(Figure 5). When the MCF10 progression series is grown in 3D rBM
overlay culture, there is increasing derangement of normal acinar struc-
tures that parallels their progression to malignancy. The in vitro model
thus recapitulates the stages of hyperplasia, atypical hyperplasia, and
dysplasia (Figure 5) observed in vivo in xenograft studies [3,58]. By
comparison to the apoptotic cells in the center of MCF10A acini,
apoptotic cells were increasingly scattered and infrequent in the NeoT,
AT1, and DCIS structures. After 20 days of 3D rBM overlay cul-
ture, some NeoT structures develop hollow lumens, but these acini
are abnormal by several criteria: delay in formation, smaller lumens
with thicker walls of multiple cell layers, and prominent staining for
cortical actin [with phalloidin]. AT1 structures exhibit extensive bud-
ding of lobules from the spheroids to form clusters of spheroids. In the
first few days of culture, DCIS cells proliferate to form small clumps,
but the clumps do not form organized spheroids. Instead, DCIS cells
form sheets and cords, with multilayers of cells that can be seen to spo-
radically invade into the rBM.
Partial Reversion of Morphology of MCF10 Progression
Series By DN-PAK1
MCF10A cells form well-developed acinar structures in 3D overlay
rBM culture, and so this can be used as an assay for oncogenic effects
that may participate in breast cancer progression, such as cell prolifer-
ation, motility, polarity, or cell–cell adhesion that may affect the archi-
tecture [59]. PAK1 overexpression and activation correlate with
inhibition of hollow lumen formation and promotion of lobular bud-
ding, which are the most typical phenotypic changes of the MCF10
progression series in 3D overlay rBM culture. Therefore, we tested
whether down regulation of PAK1 activity may reverse these pheno-
typic changes. As shown in Figure 6, after 10 days of 3D culture, the
two DN-PAK1 constructs greatly increased the formation of acini with
hollow lumens (84% and 91% of spheroids were hollow, compared to
19% in control cultures). This represented an acceleration of lumen
formation: EGFP-alone infected MCF10A control cells required more
than 2 weeks to reach the stage where the majority of spheroids were
hollow (data not shown). For NeoT cells, very few hollow lumens were
formed in control structures even by day 15. Expression of DN-PAK1
induced the formation of hollow lumens in most of the structures
(91% and 81% for PAK1.H83,86L,K299R and PAK1.K299R, re-
spectively). DN-PAK1–infected AT1 cells elicited the multilobular,
atypical hyperplastic phenotype, similar to the EGFP-infected AT1
controls, but with hollow lumens in most of the spheroids (76%
and 78%, respectively). This was quite distinct from control AT1
structures, in which hollow lumens were rarely found. These data
show a strong promotion of lumen formation by DN-PAK1, but no
effect on the budding of spheroids. There was no effect of DN-PAK1
expression on the dysplastic morphology of DCIS structures, in which
cells invaded into the rBM and formed amorphous patches.
Overexpression of wild-type or CA-PAK1 produced little ob-
servable phenotypic change in acinar development in MCF10A
(continued).
shRNA designed to decrease PAK1 expression (shRNA #1 and shRNA #2) and cultured for 2 days. (D) DCIS Cell lysates were subjected
to immunoblot analysis for PAK1 to assess knock down and were stripped and reprobed for PAK2 to assess specificity. Quantification of
results from two independent experiments demonstrated that the shRNA #2 sequence decreased PAK1 expression by 55%. (E) Trans-
duced DCIS cells were cultured in Matrigel containing DQ-collagen IV for 3 days, and images were prepared from equatorial sections of
the structures for cleavage of DQ-collagen IV (green), nuclei (blue), and expression of retroviral constructs (red). Data are representative
of results from two independent experiments. Scale bar, 10 μm.
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structures. At day 10, there was a slight effect of CA-PAK1 to reduce
luminal clearing (Figure 6), but by day 20, most of the wt-PAK1– or
CA-PAK1–infected MCF10A spheroids developed hollow lumens,
which is similar to what occurred in the EGFP-infected controls
(Figure W2). This result suggests that overexpression or activation of
PAK1 alone is not sufficient to block lumen formation by MCF10A
cells in 3D rBM overlay culture. It is possible that even if apoptotic
clearing of the lumen by anoikis was blocked, autophagy will still be
able to clear the lumen [56]. Very few hollow lumens were found in
NeoT cultures infected with wt-PAK1 or CA-PAK1, even at day 20
(Figure W2). Similarly, expression of wt-PAK1 or CA-PAK1 in AT1
cells decreased formation of hollow structures. These results suggest
that additional PAK1 activation in NeoTand AT1, which already have
abnormal luminal clearing, can further suppress this morphology.
Overexpression of PAK1 or CA-PAK1 in DCIS produced no further
aberration of the observable phenotypic change compared with EGFP
controls at day 15 (Figure 6).
Inhibition of PAK1 Inhibits Proteolysis
Progression of premalignant breast lesions is accompanied by
changes in their propensity to invade, with atypical hyperplasia clas-
sified as noninvasive and DCIS classified as preinvasive [60,61]. The
conversion from preinvasive lesions to invasive cancers observed
in vivo would be consistent with an increase in proteolytic activity,
a characteristic that can be monitored by a number of emerging im-
aging techniques. The spectrum of proteases involved in pericellular
proteolysis includes matrix metalloproteases, serine proteases, aspartic
proteases, and cysteine proteases [62], all of which can digest collagen
IV, the main component of the basement membrane of breast epi-
thelia. We have previously investigated the proteolytic activity of
BT20 human breast tumor cells in 3D [43], and this assay has also
been well-documented recently for many other cancer cells [63].
Briefly, DQ-collagen IV is so heavily labeled with fluorescein that
the fluorescence is quenched. On hydrolysis to single dye–labeled
peptides by proteases, the quenching is relieved, and the fluorescence
can be visualized by microscopy. To determine whether PAK1 expres-
sion and activity regulate pericellular proteolysis, we infected the
MCF10 progression series cells with retroviral vectors that manipu-
late PAK1 activity and cultured them in the 3D rBM overlay system
with DQ-collagen IV. The results show that at 2 days of culture, the
MCF10A, NeoT, AT1, and DCIS cells all have measurable pericellu-
lar proteolytic activity (Figure 7A). Quantification of the pericellular
proteolytic activity was done by pixel analysis of the equatorial sec-
tion of the structures (Figure 7B). The results showed that expression
of CA-PAK1 significantly enhanced pericellular degradation of DQ-
collagen IV, whereas expression of the two DN-PAK1 mutants signifi-
cantly inhibited pericellular proteolysis (Figure 7B). To further analyze
these results, we also performed 3D reconstruction of the MCF10A
structures shown in Figure 7A to quantify the pericellular proteolysis
from the entire spheroid by voxel analysis of the z-stacked images. The
results show that the pericellular proteolysis assayed in 3D (Figure 7C )
is consistent with that measured at the equatorial plane of the struc-
tures (Figure 7B).
To further confirm PAK1 regulation of pericellular proteolysis, we
tested an alternative method to reduce PAK1 activity by knock-down
of its expression. We developed dual-sequence retroviruses that en-
coded RFP plus shRNA sequences designed to generate RNAi con-
structs to target PAK1. We tested two different shRNA sequences
against PAK1, one based on a published siRNA [40], and one that
we designed ourselves. Both shRNA retroviruses produced a selective
but modest reduction in PAK1 expression (Figure 7D) and a partial
reduction in pericellular proteolysis (Figure 7E ).
CA-PAK1 Restores Pericellular Proteolysis That Has Been
Blocked By Rac Inhibition
We tested yet another alternative method to confirm the link be-
tween PAK1 activity and pericellular proteolysis. One of the most
important and well-documented mechanisms for PAK1 activation
is through its interaction with Rac1. The small-molecule inhibitor
of Rac, which inhibits PAK1 activation in this system (Figure 1C ),
greatly reduced pericellular proteolysis in the 3D rBM overlay DQ-
collagen IV assay (Figure 8, A and B). Overexpression of CA-PAK1
restored pericellular proteolysis to 3D rBM cultures that had been
treated with NSC23766 (Figure 8, C and D). DN-PAK1 did not
affect the residual pericellular proteolysis that remained in the pres-
ence of the Rac inhibitor. The rescue of inhibition by CA-PAK1 sug-
gests that the effect of the Rac inhibitor on pericellular proteolysis is
selective and not likely due to any off-target effects on other path-
ways. These results are consistent with a pathway in which Rac
activation of PAK1 regulates pericellular proteolysis during preneo-
plastic progression in the MCF10 progression series.
Discussion
PAK1 plays important functional roles in human breast cancer (re-
cently reviewed in the study of [18]). For example, PAK1 is often
overexpressed in breast tumors [17,64]. In some cases, there is gene
amplification [19] while PAK1 mRNA also increases in a hypoxic
model of the tumor microenvironment [65]. Serial analysis of gene
expression demonstrates that PAK1 overexpression occurs during the
premalignant conversion of normal epithelium to DCIS [26], and
our data show that PAK1 expression is selectively upregulated in
the MCF10A progression series in vitro (this study), where it can
coordinate aberrant cell survival, through resistance to anoikis [27],
and altered pericellular proteolysis (this study). The 11q13 locus that
includes PAK1 is not amplified in the MCF10 series [66]. Thus, our
results provide a defined premalignant progression series that recapi-
tulates in vitro the upregulation of PAK1 that is seen in human dis-
ease and further suggest a new aspect for the potential significance of
PAK1 in the regulation of pericellular proteolysis.
Disruption of polarized architecture is a prominent phenotypic
change that is characteristic of carcinoma progression. Rac1 is known
to control epithelial polarity [67,68]. PAK1 is an immediate down-
stream effector of Rac1 that regulates microtubule, actin, and micro-
filament organization, which are critical for maintenance of the
cytoskeleton and polarity. Rac1 activity is tightly controlled to main-
tain normal epithelial polarity; either hyperactivity, by expression
of CA-Rac1, or hypoactivity, by expression of DN-Rac1, disrupts
multicellular epithelial architecture [67,68]. Similarly, physiologically
relevant levels of PAK1 activity are needed for both mammary gland
development and normal epithelial function [69]. Hyperactive and
hypoactive PAK1 both disrupt cell polarity. DN-PAK1 promoted
hollow lumen formation in the MCF10 progression series, which
may be partially due to the reestablishment of cell polarity that
had been suppressed by overactivated PAK1. Activated PAK1 can
lead to phosphorylation of the proapoptotic proteins BAD and
BIM, thus inactivating cell apoptosis [70,71], and also couples to
the NF-κB pathway [28]. DN-PAK1–induced luminal cell death
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may be due to restored anoikis and suppressed survival in the luminal
cells. We have previously shown that active PAK1 rescues MCF10A
cells from undergoing anoikis [27]. Although DN-PAK1 promoted
hollow lumen formation in MCF10A, NeoT, and AT1 cells, DN-
PAK1 was not able to reverse the multilobular morphology of AT1
cells. Further, DN-PAK1 did not reverse the dysplastic phenotype of
DCIS in 3D rBM overlay culture.
DN-PAK1 inhibition of proliferation, migration, and pericellular
proteolysis may be produced through suppression of multiple down-
stream pathways that diverge from PAK1. Some of these pathways
Figure 8. A Rac/PAK1 pathway regulates pericellular proteolysis in the MCF10 progression series grown in 3D rBM overlay culture. (A)
MCF10 series cells were cultured for 2 days in Matrigel/DQ-collagen IV with or without 75 μM NSC23766. Confocal fluorescent images
taken at the equatorial plane of structures show live cell nuclei (blue; DRAQ5 staining) and pericellular proteolysis (green). Scale bar, 10 μm.
(B) Quantification of the green signals from the equatorial cross-sections of three to nine structures for each condition. The data are pre-
sented as average pixel intensity per cell, with cell number determined by counting of DRAQ5-labeled nuclei. Inhibition of Rac greatly
inhibits pericellular proteolysis in all cell lines (P < .05). (C) MCF10 series cells were infected with control retroviruses that only expressed
RFP, or bicistronic constructs expressing RFP plus wild-type PAK1 (wt), CA-PAK1 (423E), or two forms of DN-PAK1 (83,86L,299R or 299R)
and were cultured for 2 days in Matrigel containing DQ-collagen IV in the presence of 75 μM NSC23766. The data are equatorial sections
of the cells and show cleavage of DQ-collagen IV (green), the nuclei (blue), and the expression of retroviral constructs (red). Scale bar,
10 μm. (D) Quantification of the green signals from the equatorial cross-sections of three to eight structures for each condition. The data
are presented as average pixel intensity per cell, with cell number determined by counting of DRAQ5-labeled nuclei. Expression of CA-
PAK1 significantly increases pericellular proteolysis in all cell lines that had been treated with NSC23766 (P < .05).
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have been well documented. For example, increased PAK1 expression
in breast cancer cells stimulates the expression of cyclin D1, a cell cycle
factor that promotes G1–S phase progression and cell proliferation
[26], whereas PAK1-dependent activation of LIM kinase [54], Arp2/3
[72], and filamin A [73] regulates actin cytoskeleton reorganization,
cell motility, and migration. In this study, we did not find that in-
hibition of migration/invasion by PAK1 correlated with effects on
the LIM kinase/cofilin pathway, but rather tracked more closely with
reduction in pericellular proteolysis. Nevertheless, the ability of DN-
PAK1 and the Rac inhibitor to suppress pericellular proteolysis may
also be related to the regulation of actin kinetics. There is a ring of
dense cortical F-actin filaments at the apical pole of epithelial cells that
can form a physical barrier for exocytotic vesicle release [74,75]. PAK1
activation leads to reorganization of cortical actin and can therefore
facilitate lysosomal exocytosis [76].
Although we find that inhibition of PAK1 can reduce proliferation,
migration/invasion, and proteolysis, and can also promote luminal
clearing in the 3D rBM overlay culture system, the major significant
effect for CA-PAK1 is an increase in pericellular proteolysis. The re-
sults thus suggest that PAK1 activity may be necessary, but not suffi-
cient, for premalignant progression in the MCF10 series. Although
in vitro assays in 3D rBM overlay culture and in vivo assays as xeno-
grafts show progressive morphologic changes of the MCF10 series, our
results did not suggest that overexpression of wt-PAK1 or CA-PAK1 is
sufficient to drive phenotypic transformation. These results, therefore,
do not directly correlate with the progressively elevated level of PAK1
expression and activation that occurs in the MCF10 series. One expla-
nation could be that the culture media necessary for growth of the
MCF10 series may cause chronic activation of PAK1 that partially sup-
pressed the intrinsic differences in PAK1 expression and activation and
their effects on phenotypic changes in the 3D rBM overlay culture
conditions. Another possibility is that overactivated PAK1 may need
to cooperate with other molecular alterations to drive the premalignant
progression of MCF10A cells. An example of this kind of cooperation
with other factors is that active Rac1-induced disruption of cell polar-
ity must collaborate with active Akt-induced hyperproliferation to pro-
duce amorphous structures in 3D-cultured T-2 breast cancer cells [77].
It is also likely that the ability of overactivation of PAK1 to drive in-
duction of phenotypic changes is cell type–dependent. For example,
expression of CA-PAK1 in MCF-7, a breast cancer cell line that forms
invasive ductal carcinoma in vivo, increases cell motility and inva-
siveness [24]. Different cell types may have different patterns of intra-
cellularly expressed genes with which PAK1 could collaborate to
produce transformation.
Structural and functional studies have depicted PAK1 as an in-
terconnection point in cellular signal transduction. PAK1 kinase activ-
ity can be induced by interaction with Rac/Cdc42 through its CRIB
domain, followed by autophosphorylation on T423 in its kinase do-
main. PAK1 also binds to PIX [10], a Rac1 guanine nucleotide ex-
change factor, and to NCK [78], an adaptor protein that interacts
with receptor tyrosine kinases and focal adhesion kinase. These inter-
actions localize PAK1 to focal complexes and regulate actin depolymer-
ization. PAK1.K299R is an ATP binding–deficient mutant that is
kinase-dead [79], whereas PAK1.H83,86L,K299R is a double mutant
that is both Rac/Cdc42 binding–deficient and kinase-dead. Our re-
sults show that both these mutants exhibited significant inhibitory ef-
fects on cell proliferation, migration, pericellular proteolysis and
anoikis. These inhibitions could be ascribed to the kinase-dead nature
of the two mutants in that they can tether the upstream regulators and
downstream effectors of PAK1 and knock-down the endogenous
PAK1 activity. In proliferation assays, PAK1.K299R exhibited stronger
inhibition than PAK1.H83,86L,299R, which might have resulted
from more upstream inhibition by the former mutant than the latter,
which lacks the ability to bind Rac/Cdc42. Activated Rac1, but not
Cdc42, directly correlates with increased metastatic potential in a panel
of cell variants derived from a single metastatic breast cancer cell line,
MDA-MB-435; expression of a constitutively activated Rac1 results in
a more invasive and motile phenotype whereas expressing a DN Rac1
decreases invasiveness and motility [80]. Therefore, it is possible that
the elevated PAK1 activation level in the MCF10 progression series
might have resulted from, in part, overactivated Rac. By inhibiting
Rac1 with a selective inhibitor, NSC23766, PAK1 activation levels
were significantly suppressed. This suppression of PAK1 activity by
Rac inhibition greatly inhibited pericellular proteolysis and interest-
ingly, this inhibition could be largely reversed by overexpression of
CA-PAK1, which has kinase activity that is independent of Rac. Con-
sidering that Rac is upstream of PAK1 and regulates several pathways
in addition to PAK1, Rac may not prove to be an effective therapeutic
target for breast cancer. Conversely, and in light of the recent success of
other selective inhibitors of kinase targets [81], drugs that effectively
target PAK1 [82] may be a feasible approach to inhibition of breast
cancer progression. In addition to the roles in premalignant progres-
sion that have been the focus of this study, PAK1 mediates the action
of growth factors on the motility and invasiveness of human breast
cancer cells [83], stimulates cyclin D1 expression [17,84], promotes
their anchorage-independent growth [23,24], and supports epithelial-
to-mesenchymal transition [85]. Recently, the level of nuclear PAK1
has been strongly associated with tamoxifen resistance in breast cancer
patients through phosphorylation of the estrogen receptor [45,86],
which should further stimulate interest in the development of selective
PAK1 inhibitors for breast cancer therapy [87].
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Figure W1. Overexpression of PAK1 constructs in the MCF10 progression series does not affect the LIM kinase/cofilin pathway. Cells
were infected with retroviruses expressing the indicated PAK1 constructs. Cell lysates equalized for protein content were subjected
to Western blot analysis for phospho-LIM kinase or phospho-cofilin. Note that the specific phospho-cofilin signal runs just above a
nonspecific band and is indicated by an arrowhead. Results are representative of results from three independent experiments.
Figure W2. Overexpression of wild-type or CA-PAK1 suppresses luminal clearing in NeoT cells. MCF10A and NeoT cells were trans-
duced as indicated. The structures were fixed after 20 days of 3D rBM overlay culture, and the nuclei were stained with DAPI. Confocal
sections at an equatorial plane through the structures are shown as merged images of nuclei (blue) and EGFP reporter (green). Data are
representative of results from three independent experiments. Scale bar, 50 μm.
